Placeholder Banner

HHS Drug Importation Plan a "Misguided Attempt to Keep an Ill-Informed Campaign Promise"

July 31, 2019
Media Contact
Brian Newell
202.312.9268

Following the introduction of the Trump administration’s drug importation proposal, BIO’s President and CEO Jim Greenwood issued the following statement:

“There is simply no way to adopt an importation scheme that doesn’t jeopardize the health and well-being of America’s patients. That’s been the judgment of past FDA commissioners who served under both Republican and Democratic administrations. Not only will this undermine the safety of our nation’s drug supply, but nonpartisan budget experts have said that the costs of implementing drug importation will largely outweigh any savings the Administration may hope to achieve. This is a misguided attempt to keep a ill-informed campaign promise. The burden is on the leadership of the Department of Health and Human Services to ensure this actually leads to lower costs for consumers—not just for insurance companies and pharmacy benefit managers—and no harm is inflicted on patients and local communities.”

Discover More
The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO's Chief Advocacy Officer…
Representatives John Joyce, M.D. (R-PA) and Wiley Nickel (D-NC) today introduced the Optimizing Research Progress Hope And New Cures (ORPHAN Cures Act). BIO President and CEO, Rachel King, made the following remarks: "This legislation is a welcome…
The Biden Administration today unveiled the first 10 prescription drugs that will be subject to price controls under the Inflation Reduction Act (IRA). Rachel King, BIO interim President and CEO, made the following statement: The Medicare price…